

## RESPONSE

Endothelial calcium-activated  $K^+$ -channels and EDHF signalling

British Journal of Pharmacology (2003) 140, 226. doi:10.1038/sj.bjp.0705426

In recent years, good evidence has emerged that an elevation of intracellular  $[Ca^{2+}]_i$  and subsequent activation of endothelial  $IK_{Ca}$  and  $SK_{Ca}$  inducing hyperpolarization are required for the initiation of EDHF-mediated responses (for review, see Busse *et al.*, 2002). Thus, among the scientific community, there was already considerable opinion that besides other proposed mechanisms such as cytochrome *P450* enzymes, the activation of these hyperpolarizing  $K_{Ca}$  channels in the endothelium is of pivotal importance for the generation of the EDHF signal in many vessels. However, in the past, the use of pharmacological tools, for example, ion channel modulators of weak or doubtful selectivity, might have hampered or even obscured the identification of the signal transduction mechanisms underlying EDHF-mediated vasodilatation. Thus, retrospectively, results from studies using pharmacological tools of low selectivity should be interpreted more cautiously. The purpose of our work was to use new selective pharmacological tools, that is, the highly selective  $IK_{Ca}$  inhibitors TRAM-34 and

TRAM-39 (Wulff *et al.*, 2000) to reveal the involvement of the endothelial  $IK_{Ca}$  in endothelial hyperpolarization and thus EDHF-mediated vasodilatation. Overall, we think that highly selective tools are needed to ascertain the involvement of a specific mechanism, especially when referring to the involvement of ion channels. Also, we agree that besides many other articles mentioned, the work of Garland & Plane (1996) demonstrating that a combination of apamin and charybdotoxin inhibits EDHF-mediated responses, as well as the article by Busse *et al.* (2002), reviewing the historical background, are credited as important contributions in the elucidation of mechanism of EDHF signaling.

\*<sup>1</sup>Ralf Köhler and <sup>1</sup>Ines Eichler

<sup>1</sup>Department of Nephrology, Medical Center Benjamin Franklin, Freie Universität Berlin, Hindenburgdamm 30, 12200 Berlin, Germany

## References

- BUSSE, R., EDWARDS, G., FELETOU, M., FLEMING, I., VANHOUTTE, P.M. & WESTON, A.H. (2002). EDHF: bringing the concepts together. *Trends Pharmacol. Sci.*, **23**, 374–380.
- GARLAND, C.J. & PLANE, F. (1996). *Endothelium-Derived Hyperpolarizing Factor*. Harwood Academic Publishers: New York, pp. 173–179.
- WULFF, H., MILLER, M.J., HANSEL, W., GRISSMER, S., CAHALAN, M.D. & CHANDY, K.G. (2000). Design of a potent and selective inhibitor of the intermediate-conductance  $Ca^{2+}$ -activated  $K^+$  channel,  $IK_{Ca1}$ : a potential immunosuppressant. *Proc. Natl. Acad. Sci. U.S.A.*, **97**, 8151–8156.

(Received June 3, 2003  
Accepted June 20, 2003)